Robert F. Kennedy Jr.'s record of questioning childhood vaccine safety came under fire from a key Republican at the Trump HHS pick's confirmation hearing.
Caroline Kennedy said in a scathing letter about her cousin, Robert F. Kennedy Jr., that she felt "an obligation to speak out."
In a contentious confirmation hearing to become the nation’s top health official, Robert F. Kennedy Jr. struggled Wednesday to answer questions about Medicare and Medicaid, programs that affect tens of millions of Americans,
Robert F. Kennedy Jr., Tulsi Gabbard and Kash Patel testify before Senate committees on Capitol Hill Thursday as urgency builds to confirm President Donald Trump’s Cabinet nominations.
Robert F. Kennedy Jr., President Trump’s pick to run the Department of Health and Human Services, squared off with Democratic senators for more than four hours in a contentious confirmation hearing before the Senate Finance Committee.
If approved, Kennedy will control a $1.7 trillion agency that oversees food and hospital inspections, hundreds of health clinics, vaccine recommendations and health insurance for roughly half the country.
RFK Jr. claimed he is not “anti-vaccine” and appeared unfamiliar with key aspects of healthcare insurance programs in his confirmation hearing.
Robert F. Kennedy Jr. was confronted with a number of his baseless claims and a vexing abortion issue. But Republican senators treaded lightly.
In a scathing letter Tuesday, Caroline Kennedy warned senators about her cousin, Robert F. Kennedy Jr., calling him a "predator."
Robert F. Kennedy Jr. is an environmental lawyer, author and political activist who has suspended his independent presidential campaign and thrown his support behind former President Donald J.
As he seeks to lead the health department, Mr. Kennedy wore a thin tie dotted with feathered creatures to cap a classic suit.
From law firm payouts to endorsements and book deals, nominee for HHS secretary Robert F. Kennedy Jr. raked in at least $12 million in the past two years. RFK Jr. petitioned the FDA in 2021 to ...